Clinical Trial Update: Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments [Phase 4]

View source ↗

Summary

Phase 4 trial update of intravitreal ranibizumab for pigment epithelial detachments has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pigment Epithelial Detachment

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University Hospital Muenster | Conditions: Pigment Epithelial Detachment | Phase 4 | Status: COMPLETED